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Primary immunodeficiency (PID) disorders that predispose patients to recurrent infections
require immunoglobulin (Ig) replacement therapy. Ig replacement therapy has been stated
as beneficial, although the optimal IgG trough level to be maintained over time in order to
minimize infectious risk has not been established. The most common route of administra-
tion of Ig has been intravenously, although there are different options, one of them being the
subcutaneous route. Ig replacement therapy has been a life-saving treatment for patients
suffering from primary and secondary antibody immunodeficiency.The key role of regular Ig
replacement in patients with antibody deficiencies is related to the ability to provide specific
antibodies that could not be produced by these patients as demonstrated by the reduction
of severe infections such as meningitis and pneumonia.The therapeutic benefits of Ig may
also be due to an active role in various anti-inflammatory and immunomodulatory activi-
ties, which may complicate the clinical picture of PID. Anti-inflammatory activities are seen
more generally when intravenous Ig is administered at high dose.The immunomodulatory
and anti-inflammatory activities are important not only in the treatment of autoimmune
diseases but also in patients suffering from immunodeficiency.
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INTRODUCTION
Primary immunodeficiency (PID) disorders that predispose
patients to recurrent respiratory, skin, and gastrointestinal infec-
tions, require immunoglobulin (Ig) replacement therapy. Com-
mon variable immunodeficiency disease (CVID) is one of the
most frequent PID characterized by decreased serum levels of all
Ig isotypes and recurrent bacterial infections encompassing a het-
erogeneous group of diseases whose unifying feature is hypogam-
maglobulinemia (1). The etiopathogenesis of CVID has not been
yet fully elucidated. Major progress toward elucidating CVID has
been achieved with the identification of defects not only in B-cells,
which are directly responsible for antibody production, but also
in other immune cells implicated in the generation of an effec-
tive humoral response, including antigen-presenting cells (APC)
and, in a significant proportion of these patients, helper T cells (2–
4). Overall, the disorder is characterized by a defective antibody
production by B lymphocytes. Although the number of B-cells
may be normal, patients with CVID show extremely decreased
serum IgG, IgA, and, occasionally, IgM concentrations. The treat-
ment of choice for CVID patients is replacement Ig therapy. A
common route of administration of Ig has been intravenously
(IVIg) although today there are different options, one of them
being the subcutaneous route (SCIg). Ig replacement therapy has
been a life-saving treatment for patients suffering from primary
and secondary antibody immunodeficiencies, in fact, a recent pub-
lished meta analysis of clinical trials in PID quantitatively confirms
that trough IgG levels directly impact clinical outcomes (5). How-
ever, the optimal IgG trough level to be maintained over time
in order to minimize infectious risk, has not been established
and probably it should be individualized (6–8). The key role
of regular Ig replacement in patients with antibody deficien-
cies is related to the ability to provide specific antibodies that
could not be produced by these patients as demonstrated by the
reduction of severe infections such as meningitis and pneumo-
nia (9). The therapeutic benefits of Ig may also be due to an
active role in various anti-inflammatory and immunomodula-
tory activities. In fact, clinical and immunopathological aspects
of the association between CVID and autoimmune or inflam-
matory disorders have been extensively reported in a number of
patients (10, 11). On the other hands, Ig preparations other than
antibodies to superantigens and pathogens also contain numer-
ous soluble proteins with biologic activity such as cytokines,
chemokines, soluble cytokine receptors, and receptor antagonists.
In fact, since they were first administered to patients with anti-
body deficiency disorders over 50 years ago, human intravenous
Ig preparations have been used successfully to treat a rapidly
increasing number of autoimmune and inflammatory disorders,
among which are a series of cutaneous autoimmune and inflam-
matory diseases (12). Despite the identification of protective,
immunomodulatory, and anti-inflammatory activities in various
diseases, the benefits of Ig are not easily explained and probably
depend by several mechanisms. Anti-inflammatory activities are
seen more generally when intravenous Ig is administered at high
dose. The immunomodulatory and anti-inflammatory activities
are important not only in the treatment of autoimmune dis-
eases but also in patients suffering from immunodeficiency. In
this article, the protective and immunoregulatory mechanisms are
summarized.
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IMMUNOGLOBULIN PREPARATION
The major component of IVIg and SCIg preparations is the IgG
fraction, which is pooled from human plasma of several thou-
sands of donors using a procedure that varies somewhat between
manufacturers, but results in a product that is a relatively pure
concentrate of intact monomeric IgG, with a half-life of 3 weeks,
and with small amounts of IgA and IgM. IgG subclasses (IgG1,
IgG2, IgG3, and IgG4) in IVIg and SCIg products have a dis-
tribution similar to that found in normal human plasma. IgG
aggregates are virtually absent from the majority of Ig prepara-
tions even if up to 1–10% of IgG can be found in dimeric form
in most of IVIg preparations. The processes of purification have
the potential to adversely affect the final quality and biological
activity of IVIG/SCIG in terms of efficacy and safety (13). Nat-
ural antibodies and autoantibodies are prominent in commercial
preparations. A wide range of specificities have been identified
within Ig preparations including idiotypes of Ig itself, T cell recep-
tor, cell surface molecules such as CD4, CD5, Fas, BAFF, cytokines,
and cytokine receptors, such as IL-1; IL-6, tumor necrosis fac-
tor (TNF)-α, chemokine receptors, molecules such as sialic acid
binding Ig-like lectin (Siglec)-8 and -9 or major histocompati-
bility complex (MHC) molecules; natural autoantibodies of IgG
isotype directed against the human FcγRIII (CD16) and FcγRII
(CD32) (14–16).
MECHANISMS OF IVIg IN THE CORRECTION OF HUMORAL
DEFECTS
The underlying mechanisms of therapeutic effects of IVIg/SCIg in
PID are not completely understood, the major aim is to prevent
life-threatening bacterial or viral infections (Figure 1). IVIg/SCIg
act mainly as a reconstitution therapy, providing patients with
pathogen-specific antibodies able to protect from infectious. The
unique structure of the Ig molecule ensures the large repertoire of
specificities of the antibodies. To maintain the polyclonal nature of
the antibody repertoire that is normally present in serum of healthy
subjects naturally exposed to microbial agents or submitted to
vaccines is a crucial step during the preparation of commercial Ig.
Considering that IVIg preparations are generated from adults who
have been vaccinated and have encountered a multitude of path-
ogenic microorganisms, serum IgG can comprise more than 100
million unique specificities. The clinical and functional activities
can be distinguished by the infused amounts. In fact, a monthly
Ig dosage of at least 400 mg/kg body weight is recommended and
is most often sufficient as replacement therapy (17). The activ-
ities of Ig molecules present in IVIg/SCIg preparations, such as
bactericidal effect through complement system activation, viral
neutralization, inactivation of toxins, and opsonization, are crucial
for the induction of an effective immune response against several
microorganisms and their toxic products. As known, IgG antibod-
ies include two functional portions as the F(ab′) fragment, which
is responsible for antigen recognition, and the fragment crystal-
lizable (Fc), crucial for activating the mechanisms of immunity
by interacting with Fcγ receptors on B-cells and other cells of
the innate immune system belonging to the phagocytic system.
The Fc fragment is also crucial for the activation of complement
and for the clearance of microorganisms (18). B-cells from several
CVID patients seem to be not intrinsically defective as they express
CD40 and proliferate significantly upon anti-CD40 stimulation.
Interestingly, IVIg at “replacement dose” (10 mg/ml) are able to
interact with B-cells, also inducing significantly higher prolifera-
tion of B-cells than anti-B cell receptor (BCR) stimulation alone.
In addition, IVIg replacement is able to induce Ig synthesis ex novo
by B-cells (19). Therefore, IVIg therapy, at least in some CVID,
is able to modulate B cell functions and it is a passive transfer
of antibodies. As previously mentioned, PID are a heterogeneous
group of disorders that affect distinct components of the innate
FIGURE 1 | Mechanisms of action of IVIg in PID.
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and adaptive immune system. Defects not only in B-cells, which
are directly responsible for antibody production, but also in other
immune cells such as APC and T helper (Th) cells, represent the
molecular basis of CVID (20, 21). It has been shown that in CVID
patients the humoral defects may be associated with immunolog-
ical abnormalities of T cell compartment and myeloid dendritic
cells (mDC), characterized by low counts of CD4+ T cells, high
expression of HLA-DR and CD38 (also on CD8+ T cells), sup-
pressed number of mDC, highly positive for CD80 and CD83.
Several of these cellular perturbations are partially corrected by
the treatment with IVIg. In fact, the introduction of therapy may
lead to CD4+ T cell recovery and decline in CD8+ T cells and
mDC activation. These effects are likely sustained by an improved
immune control of infections due to humoral reconstitution (22).
MECHANISMS OF ACTION OF IVIg IN COMORBIDITY OF PID
The use of IVIg has been firmly established for the treatment
of a wide variety of autoimmune and inflammatory diseases,
due to their immune-regulatory and anti-inflammatory effects
(Figure 1). Some of these autoimmune diseases may be a comor-
bidity of PID, especially CVID, thus sustaining an additional role,
beyond the antibody replacement, for IVIg in the treatment of
immunodeficiencies. For example, the immunoregulatory func-
tions of IVIg in PID patients explain the therapeutic effects showed
in autoimmune hemolytic anemia and/or immunothrobocitope-
nia, probably by blocking the clearance of opsonized target cells
or by suppressing antibody-dependent cell-mediated cytotoxicity.
This potential was first revealed when IVIg, used to treat a patient
with antibody deficiency, were able to restore platelets count when
concomitant thrombocytopenia occurred (23). The way in which
IVIg exert their immunomodulatory effects remain unclear, with
many pathways, probably mutually non-exclusive, in the innate
and adaptive immune systems being potentially targeted. At least
a percentage of immune modulatory effects of IVIg are depen-
dent upon the interaction between the Fc portion with the Fcγ
receptors expressed on the surface of cells as macrophages, B-cells,
natural killer (NK) cells, plasma cells, and platelets (18). For exam-
ple, as previously mentioned, it has been clearly demonstrated
that Fc fragment of IgG can be sufficient to ameliorate immune-
mediated thrombocytopenia in humans (24), by suppressing the
phagocytosis of platelets via an Fc-dependent mechanism instead
of preventing autoantibodies from binding to cells (25). Studies
performed both in mice and humans confirmed that IVIg infu-
sion is able to inhibit the mononuclear phagocytic system, usually
activated by immune complexes through activating of low-affinity
FcγRs (26). However, there is no direct proof that IVIg block the
binding of immune complexes to FcγRs. The Fc portion of Ig
not only impacts the function of activating Fc receptors but also
increase the expression of inhibitory FcγRIIB on macrophages
(27). Recent studies in animal models of idiopathic thrombocy-
topenic purpura suggest that IVIg, increasing the expression of
the Fcγ receptor IIB, may reset the threshold for cell activation by
immune complexes (18, 25). In other words, IVIg should be able
to shift the FcγR-dependent balance of activating and inhibitory
signals even more toward cell inhibition of innate immune effector
cells.
A mechanism implicated in immune-regulatory function of
IVIg preparation is also the effect on the balance between
pro- and anti-inflammatory cytokines. To this effect, antibod-
ies to IL-1 and TNF-α have been identified in addition to a
down-regulation of such cytokines (28). Furthermore, IVIg induce
anti-inflammatory cytokines such as IL-10, TGF-β, and IL-1ra
from monocytes/macrophages (28, 29). In our hands, in IVIg-
treated PID patients the raising of IL-10 after administration of
therapy was not observed in those with associated granulomatous
lung disease, thus suggesting the lack of the induction of reg-
ulatory cytokines in such subgroup of patients. Dendritic cells
represent an important source of pro-inflammatory and anti-
inflammatory cytokines and a modulation of cytokine secretion
has been shown, characterized by a decrease of IL-12 production
and enhanced secretion of IL-10 has been described. DC mat-
uration, activation, and survival are also targeted by IVIg, thus
affecting the overall APC activity with subsequent inhibition of
adaptive T cell response, including autoreactive cells (30). This lat-
ter effect is of potential relevance considering the beneficial action
in autoimmune conditions.
Dendritic cells are professional APC with superior capacity to
present both MHC-restricted and CD1-restricted antigens. DCs
may adapt their CD1 antigen presentation machinery according
to signals in the microenvironment. A role for IgG in regulating
the expression of CD1 molecules in human DCs has been shown in
in vitro experiments. In particular, it has been found that the level
of exposure to IgG regulates the CD1 expression profile during DC
differentiation, and that this is mediated by FcγRIIa. This in turn
determines whether the DCs will be biased toward activation of
CD1d-restricted regulatory NKT cells or T cells specific for lipid
antigens presented by CD1a, CD1b, and CD1c (31). Furthermore,
results obtained from patients with CVID indicate that mDCs
express elevated levels of CD1a and CD1b in the presence of low
levels of IgG in vivo, and that this aberrant expression pattern is
normalized after IVIg therapy (32). These findings are important
for our understanding of diseases associated with Ig deficiencies
and their treatment with IVIg.
Concerning the IVIg effects on apoptosis, triggered by the
interactions between CD95 (Fas) and its ligand (CD95L, FasL),
controversial data are present in literature and probably both ago-
nist and antagonist properties may be attributed to IVIg. In CVID,
an increased expression of Fas on CD3+ T cells has been demon-
strated and a further increase was shown after IVIg therapy (33).
In the context of autoimmune disease as comorbidity of PID, the
process could be important in that specific harmful T cells may be
deleted through apoptosis.
The complement system is a first line of defense against invad-
ing microorganisms, but if its activation occurs under inappro-
priate circumstances, this system may be not beneficial leading to
complement-mediated disorders characterized by cell lysis and
tissue damage. Ig plays an intriguing role in complement and
regulation. IVIg preparation contain pathogen-specific antibod-
ies and autoantibodies able to activate the effector system, but on
the other hand, the rest of the circulating Ig pool (mainly of IgG
and IgM isotype) have the capacity to attenuate damaging effects
of activated complement fragments. This latter effect seems to be
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related to a scavenger action toward complement fragments that
is dependent on a low-affinity interaction between the fragment
in question and various Ig regions (Fc binding to C3b/C4b; Fab
binding to C3a/C5a). Such immunocomplexes are then removed
by the reticuloendothelial system (34).
Even if many immunoregulatory effects have been ascribed to
IVIg, it remains unclear why high doses of IVIg are required to
obtain this activity. Some insights were gained when the role of IgG
glycosylation was addressed in animal models. Deglycosylated Ig
appeared to be unable to provide anti-inflammatory protections,
although glycan was found in only 1–3% of IgG preparation (35).
Sialylated Fc present in low amount in IVIg binds to SIGN-R1 on
macrophages leading to an increased expression of the inhibitory
FcγRIIB receptors and decreased expression of FcγRs. The over-
all result is an anti-inflammatory and anti-phagocytic effect. The
key role of the terminal sialic acid residues is confirmed by the
role of the molecules CD22 and CD33, also called SIGLEC, which
are expressed by B-cells and cells of innate immune system (36,
37). Their capacity to trigger cell inactivation is related to the acti-
vation of intracellular immunoreceptor tyrosine-based inhibitor
motifs (ITIMs). Of note, while the importance of Fc sialylation has
been clearly shown in animal models, its role in humans should be
better evaluated, and important species differences may probably
exist.
CONCLUSION
Immunoglobulin therapy is a consistently evolving practice that
provides life-saving protection to patients with PID, particularly
with antibody deficiency as well as in patients with other immune-
mediated diseases. Taking into account the growing demand of
Ig preparations not only for PID patients but also for subjects
suffering from chronic immune-mediated diseases, more clinical
trials will be required as well as basic research able to improve the
knowledge on the mechanisms of action of IVIg.
REFERENCES
1. Cunningham-Rundles C. How I treat common variable immunodeficiency.
Blood (2010) 116:7–15. doi:10.1182/blood-2010-01-254417
2. Spickett GP. Current perspectives on common variable immunodeficiency
(CVID). Clin Exp Allergy (2001) 31:536–42. doi:10.1046/j.1365-2222.2001.
01117.x
3. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes.
N Engl J Med (2000) 343:1313–24. doi:10.1056/NEJM200011023431806
4. Capitani N, Ariani F, Amedei A, Pezzicoli A, Matucci A, Vultaggio A, et al. Vav1
haploinsufficiency in a common variable immunodeficiency patient with defec-
tive T-cell function. Int J Immunopathol Pharmacol (2012) 25:811–7.
5. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough
IgG on pneumonia incidence in primary immunodeficiency: a meta-
analysis of clinical studies. Clin Immunol (2010) 137:21–30. doi:10.1016/j.clim.
2010.06.012
6. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al.
Effectiveness of immunoglobulin replacement therapy on clinical outcome in
patients with primary antibody deficiencies: results from a multicenter prospec-
tive cohort study. J Clin Immunol (2011) 31:315–22. doi:10.1007/s10875-011-
9511-0
7. Gathmann B, Mahlaoui N; CEREDIH, Gérard L, Oksenhendler E, Warnatz K,
et al. Clinical picture and treatment of 2212 patients with common variable
immunodeficiency. J Allergy Clin Immunol (2014) 134:116–26. doi:10.1016/j.
jaci.2013.12.1077
8. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of
intravenous immunoglobulin in human disease: a review of evidence by mem-
bers of the Primary Immunodeficiency Committee of the American Academy of
Allergy, Asthma and Immunology. J Allergy Clin Immunol (2006) 117:S525–53.
doi:10.1016/j.jaci.2006.01.015
9. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection out-
comes in patients with common variable immunodeficiency disorders: relation-
ship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol (2010)
125:1354–60. doi:10.1016/j.jaci.2010.02.040
10. Cunninghan-Rundles C, Bodian C. Common variable immunodeficiency: clin-
ical and immunological features of 248 patients. Clin Immunol (1999) 92:34–48.
doi:10.1006/clim.1999.4725
11. Mackay IR, Leskovsek NV, Rose NR. The odd couple: a fresh look at autoim-
munity and immunodeficiency. J Autoimmun (2010) 35:199–205. doi:10.1016/
j.jaut.2010.06.008
12. Gelfand EW. Intrevenous immune globulin in autoimmune and inflammatory
diseases. N Engl J Med (2012) 367:2015–25. doi:10.1056/NEJMra1009433
13. Martin TD. IGIV: contents, properties, and methods of industrial production –
evolving closer to a more physiologic product. Int Immunopharmacol (2006)
6:517–22. doi:10.1016/j.intimp.2005.11.005
14. Seite J, Shoenfeld Y, Youinou P, Hillions S. What is the content of the magic draft
IVIG? Autoimmune Rev (2008) 7:435–9. doi:10.1016/j.autrev.2008.04.012
15. Ravindranath MH, Terasaki PI, Maehara CY, Jucaud V, Kawakita S, Pham T,
et al. IgG purified from human sera mirrors IVIg’s HLA reactivity and recog-
nizes one’s own HLA types, but may be masked by Fab CDR peptide in the native
sera. Clin Exp Immunol (2014). doi:10.1111/cei.12450
16. Bouhlal H, Martinvalet D, Teillaud JL, Fridman C, Kazatchkine MD, Bayry J,
et al. Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.
J Clin Immunol (2014) 34:S4–11. doi:10.1007/s10875-014-0019-2
17. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous
immunoglobulins in immunodeficiencies: more than mere replacement ther-
apy. Clin Exp Immunol (2011) 164:2–5. doi:10.1111/j.1365-2249.2011.04387.x
18. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG medi-
ated through the inhibitory Fc receptor. Science (2001) 291:484–6. doi:10.1126/
science.291.5503.484
19. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, et al. Intra-
venous immunoglobulin induces proliferation and immunoglobulin synthesis
form B cells of patients with common variable immunodeficiency: a mecha-
nism underlying the beneficial effect of IVIg in primary immunodeficiencies. J
Autoimmunity (2011) 36:9–15. doi:10.1016/j.jaut.2010.09.006
20. Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable
immunodeficiency: a new look at an old disease. Lancet (2008) 372:489–502.
doi:10.1016/S0140-6736(08)61199-X
21. Capitani N, Amedei A, Rossi Paccani S, Matucci A, Vultaggio A, Del Prete GF,
et al. Impaired Th2 response in Vav1-deficient common variable immunodefi-
ciency patients with T-cell defects. J Allergy Clin Immunol (2010) 126:671–5.
doi:10.1016/j.jaci.2010.05.033
22. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Barreto de Oliveira
AK, Kokron CM, et al. IVIg immune reconstitution treatment alleviates the state
of persistent immune activation and suppressed CD4 T cell counts in CVID.
PLoS One (2013) 8:e75199. doi:10.1371/journal.pone.0075199
23. Imbach P,Barandun S,D’ApuzzoV,Baumgartner C,Hirt A,Morell A,et al. High-
dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in
childhood. Lancet (1981) 1:1228–31. doi:10.1016/S0140-6736(81)92400-4
24. Debre M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al.
Infusion of Fc g fragments for treatment of children with acute immune throm-
bocytopenic purpura. Lancet (1993) 342:945–9. doi:10.1016/0140-6736(93)
92000-J
25. Crown AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticulu-
endhotelial system function and ameliorates murine passive-immune throm-
bocytopenia independent of anti-idiotype reactivity. Br J Haematol (2001)
115:679–86. doi:10.1046/j.1365-2141.2001.03136.x
26. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies
with specificity for soluble antigens mimic the therapeutic effects of intravenous
IgG in the treatment of autoimmune disease? J Clin Invest (2005) 11:155–60.
doi:10.1172/JCI200522753
27. Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV. Pathology and protection
in nephrotoxic nephritis is determined by selective engagement of specific Fc
receptors. J Exp Med (2006) 203:789–97. doi:10.1084/jem.20051900
28. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflam-
matory diseases with intravenous immune globulin. N Engl J Med (2001)
345:747–55. doi:10.1056/NEJMra993360
Frontiers in Immunology | Primary Immunodeficiencies January 2015 | Volume 5 | Article 690 | 4
Matucci et al. Immunoglobulins in PID
29. Reinhold D, Perlov E, Schrecke K, Kekow J, Brune T, Sailer M. Increased
blood concentration of TGF-beta isoforms after treatment with intravenous
immunoglobulins (i.v.IG) in patients with multiple sclerosis. J Neuroimmunol
(2004) 152:191–4. doi:10.1016/j.jneuroim.2004.03.018
30. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A,
et al. Inhibition of maturation and function of dendritic cells by intravenous
immunoglobulin. Blood (2003) 101:758–65. doi:10.1182/blood-2002-05-1447
31. Smed-Sörensen A, Moll M, Cheng TY, Loré K, Norlin AC, Perbeck L, et al.
IgG regulates the CD1 expression profile and lipid antigen-presenting func-
tion in human dendritic cells via FcgammaRIIa. Blood (2008) 111:5037–46.
doi:10.1182/blood-2007-07-099549
32. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Oliveira AK,
Kokron CM, et al. Dysregulated CD1 profile in myeloid dendritic cells in
CVID patients is normalized by IVIg treatment. Blood (2013) 121:4963–4.
doi:10.1182/blood-2013-04-499442
33. Artac H, Kara R, Reisli I. In vivo modulation of expression of Fas and CD25 by
intravenous immunoglobulin in common variable immunodeficiency. Clin Exp
Med (2010) 10:27–31. doi:10.1007/s10238-009-0061-1
34. Basta M. Ambivalent effect of immunoglobulins on the complement system.
Mol Immunol (2008) 45:4073–9. doi:10.1016/j.molimm.2008.07.012
35. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of
immunoglobulin G resulting from Fc sialylation. Science (2006) 313:670–3.
doi:10.1126/science.1129594
36. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglec and immunoregulation.
Ann Rev Immunol (2012) 30:357–92. doi:10.1146/annurev-immunol-020711-
075018
37. Crocker PR, Redelinghuys P. Siglec as positive and negative regulators of the
immune system. Bioch Soc Trans (2008) 36:1467–71. doi:10.1042/BST0361467
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 16 October 2014; accepted: 23 December 2014; published online: 12 January
2015.
Citation: Matucci A, Maggi E and Vultaggio A (2015) Mechanisms of action of Ig prepa-
rations: immunomodulatory and anti-inflammatory effects. Front. Immunol. 5:690.
doi: 10.3389/fimmu.2014.00690
This article was submitted to Primary Immunodeficiencies, a section of the journal
Frontiers in Immunology.
Copyright © 2015 Matucci, Maggi and Vultaggio. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org January 2015 | Volume 5 | Article 690 | 5
